Treatment-Resistant Depression

Midwest CEPAC
May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials

10/10/2018 – 10/30/2018
Open Input Period
10/31/2018
Draft Scoping Document
10/31/2018
Stakeholder List
10/31/2018 – 11/20/2018
Public Comments
11/29/2018
Revised Scoping Document
01/14/2019
Research Protocol
02/05/2019
Model Analysis Plan
03/21/2019
Draft Voting Questions
03/21/2019
Draft Evidence Report
03/21/2019 – 04/17/2019
Public Comments
05/09/2019
Evidence Report
05/09/2019
Revised Voting Questions
05/09/2019
Response to Comments
05/23/2019
Meeting Agenda
05/23/2019
Evidence Presentation
06/20/2019
Final Evidence Report and Meeting Summary
06/20/2019
Report-at-a-Glance